AbbVie Broadens Qulipta Migraine Indication As Anti-CGRP Competition Grows

Approval Comes Month After New Pfizer Product

 
• By Mandy Jackson

AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.

Tired african-american business woman with headache at office, feeling sick at work, copy space
Qulipta cut headache days significantly for chronic migraine sufferers

More from New Products

More from Scrip